Taha Merghoub

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3122421/publications.pdf

Version: 2024-02-01

169 papers	37,410 citations	8749 75 h-index	4988 167 g-index
190 all docs	190 docs citations	190 times ranked	43330 citing authors

#	Article	IF	Citations
1	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nature Reviews Clinical Oncology, 2022, 19, 37-50.	12.5	350
2	Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism. Science Advances, 2022, 8, eabm4552.	4.7	5
3	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	13.7	44
4	Plasma secretome analyses identify IL-8 and nitrites as predictors of poor prognosis in nasopharyngeal carcinoma patients. Cytokine, 2022, 153, 155852.	1.4	1
5	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature Communications, 2022, 13, 1935.	5.8	37
6	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/â˜' trastuzumab in patients with breast cancer brain metastases. Npj Breast Cancer, 2022, 8, 50.	2.3	17
7	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 3990-4002.	3.2	15
8	Neutrophil phenotypes and functions in cancer: A consensus statement. Journal of Experimental Medicine, 2022, 219, .	4.2	119
9	Fundamental immuneâ€“oncogenicity trade-offs define driver mutationÂfitness. Nature, 2022, 606, 172-179.	13.7	23
10	Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature, 2022, 606, 389-395.	13.7	80
11	Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. Cancers, 2022, 14, 2638.	1.7	12
12	Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. Journal of Experimental Medicine, 2022, 219, .	4.2	8
13	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine, 2022, 14, .	5.8	10
14	Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. Cell Reports, 2021, 34, 108620.	2.9	21
15	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repairâ€“proficient Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2200-2208.	3.2	51
16	CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature, 2021, 591, 652-658.	13.7	187
17	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell, 2021, 184, 4032-4047.e31.	13.5	131
18	Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ TÂcells in tumors. Immunity, 2021, 54, 1561-1577.e7.	6.6	260

#	Article	IF	Citations
19	Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ TÂcell immunity. Cancer Cell, 2021, 39, 973-988.e9.	7.7	93
20	Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 5131-5140.	3.2	40
21	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature, 2021, 596, 126-132.	13.7	234
22	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	5.8	54
23	Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia. , 2021, 9, e002569.		9
24	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. Cancer Discovery, 2021, 11, 1212-1227.	7.7	139
25	Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI Insight, 2021, 6, .	2.3	2
26	Isoform specific anti-TGFÎ² therapy enhances antitumor efficacy in mouse models of cancer. Communications Biology, 2021, 4, 1296.	2.0	6
27	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell, 2020, 183, 818-834.e13.	13.5	287
28	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell, 2020, 183, 363-376.e13.	13.5	206
29	Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. Archives of Biochemistry and Biophysics, 2020, 690, 108479.	1.4	30
30	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature Communications, 2020, 11, 3800.	5.8	61
31	Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature Communications, 2020, 11, 4011.	5.8	198
32	Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets. Annals of Translational Medicine, 2020, 8, 1031-1031.	0.7	5
33	Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. Cancer Research, 2020, 80, 4233-4243.	0.4	18
34	CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nature Immunology, 2020, 21, 298-308.	7.0	326
35	ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature, 2020, 579, 130-135.	13.7	229
36	In vitro assays for effector T cell functions and activity of immunomodulatory antibodies. Methods in Enzymology, 2020, 631, 43-59.	0.4	5

#	Article	IF	Citations
37	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1327-1337.	3.2	90
38	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
39	iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. Cancer Research, 2020, 80, 1681-1692.	0.4	31
40	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical Cancer Research, 2020, 26, 2849-2858.	3.2	74
41	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nature Immunology, 2019, 20, 1231-1243.	7.0	217
42	Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell Reports, 2019, 27, 806-819.e5.	2.9	51
43	One checkpoint may hide another: inhibiting the TGFÎ² signaling pathway enhances immune checkpoint blockade. Hepatobiliary Surgery and Nutrition, 2019, 8, 289-294.	0.7	5
44	Rational design of anti-GITR-based combination immunotherapy. Nature Medicine, 2019, 25, 759-766.	15.2	180
45	Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect. Frontiers in Immunology, 2019, 10, 604.	2.2	40
46	Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. OncoImmunology, 2019, 8, e1581528.	2.1	20
47	Polyphenols from Pennisetum glaucum grains induce MAP kinase phosphorylation and cell cycle arrest in human osteosarcoma cells. Journal of Functional Foods, 2019, 54, 422-432.	1.6	12
48	Massively parallel sequencing analysis of benign melanocytic naevi. Histopathology, 2019, 75, 29-38.	1.6	12
49	In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. Journal of Clinical Investigation, 2019, 129, 3435-3447.	3.9	33
50	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 2018, 378, 1976-1986.	13.9	1,495
51	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell, 2018, 33, 581-598.	7.7	393
52	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 843-852.e4.	7.7	827
53	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell, 2018, 173, 624-633.e8.	13.5	113
54	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunology Research, 2018, 6, 189-200.	1.6	102

#	Article	IF	Citations
55	Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. Journal of the National Cancer Institute, 2018, 110, 787-790.	3.0	123
56	The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. Molecular Cell, 2018, 69, 923-937.e8.	4.5	12
57	Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Molecular Therapy, 2018, 26, 1008-1019.	3.7	103
58	Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors. Clinical Cancer Research, 2018, 24, 592-599.	3.2	75
59	Molecular Determinants of Response to Antiâ€“Programmed Cell Death (PD)-1 and Antiâ€“Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Nonâ€“Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	0.8	1,109
60	Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PLoS ONE, 2018, 13, e0191926.	1.1	17
61	Strategies for Predicting Response to Checkpoint Inhibitors. Current Hematologic Malignancy Reports, 2018, 13, 383-395.	1.2	23
62	Using LIBS to diagnose melanoma in biomedical fluids deposited on solid substrates: Limits of direct spectral analysis and capability of machine learning. Spectrochimica Acta, Part B: Atomic Spectroscopy, 2018, 146, 106-114.	1.5	48
63	Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. Cancer Discovery, 2018, 8, 1006-1025.	7.7	248
64	Non-conventional Inhibitory CD4+Foxp3â˜PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell, 2018, 33, 1017-1032.e7.	7.7	112
65	PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. Journal of Clinical Investigation, 2018, 128, 1413-1428.	3.9	111
66	Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget, 2018, 9, 28702-28716.	0.8	27
67	Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma. Journal of Investigative Dermatology, 2017, 137, 1135-1143.	0.3	23
68	Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell Metabolism, 2017, 25, 358-373.	7.2	109
69	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications, 2017, 8, 14340.	5.8	110
70	HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers. Journal of Biological Chemistry, 2017, 292, 10142-10152.	1.6	28
71	Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature, 2017, 545, 452-456.	13.7	643
72	Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Science Immunology, 2017, 2, .	5.6	101

#	Article	IF	Citations
73	Curbing Tregsâ€™ (Lack of) Enthusiasm. Cell, 2017, 169, 981-982.	13.5	4
74	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Annals of Oncology, 2017, 28, 583-589.	0.6	510
75	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer Immunology Research, 2017, 5, 84-91.	1.6	126
76	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell, 2017, 170, 927-938.e20.	13.5	368
77	Blockade of surface-bound TGF-Î² on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Science Signaling, 2017, 10, .	1.6	100
78	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551, 512-516.	13.7	854
79	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature, 2017, 551, 517-520.	13.7	532
80	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS Medicine, 2017, 14, e1002309.	3.9	256
81	Antiangiogenic therapy and immune checkpoint blockade go hand in hand. Annals of Translational Medicine, 2017, 5, 497-497.	0.7	21
82	PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-15.	1.5	275
83	Abstract 3643: INCAGN1876, a unique GITR agonist antibody that facilitates GITR oligomerization. , 2017, , .		2
84	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget, 2017, 8, 69204-69218.	0.8	21
85	Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. Oncotarget, 2017, 8, 105000-105010.	0.8	10
86	Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2. American Journal of Dermatopathology, 2016, 38, 201-207.	0.3	8
87	NSCLC, early stage Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer. Annals of Oncology, 2016, 27, vi576.	0.6	14
88	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. OncoImmunology, 2016, 5, e1151595.	2.1	57
89	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunology Research, 2016, 4, 936-947.	1.6	132
90	Overcoming resistance to checkpoint blockade therapy by targeting PI3KÎ³ in myeloid cells. Nature, 2016, 539, 443-447.	13.7	661

#	Article	IF	Citations
91	In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Science Immunology, 2016, 1, aaf6925.	5.6	142
92	Clonal Abundance of Tumor-Specific CD4 + T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion. Immunity, 2016, 44, 179-193.	6.6	39
93	Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine, 2016, 6, 50-58.	2.7	113
94	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469.	6.0	2,445
95	IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients. Tumor Biology, 2016, 37, 3505-3514.	0.8	24
96	First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 3017-3017.	0.8	30
97	The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor protein. Oncotarget, 2016, 7, 45597-45607.	0.8	19
98	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget, 2016, 7, 85430-85436.	0.8	60
99	Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapy. Translational Cancer Research, 2016, 5, S1116-S1118.	0.4	0
100	Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer. Blood, 2016, 128, 861-861.	0.6	0
101	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Molecular Cell, 2015, 59, 345-358.	4.5	125
102	The New Era of Cancer Immunotherapy. Advances in Cancer Research, 2015, 128, 1-68.	1.9	41
103	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. Oncologist, 2015, 20, 789-797.	1.9	57
104	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. Science, 2015, 348, 124-128.	6.0	6,756
105	Genetics and immunology: reinvigorated. OncoImmunology, 2015, 4, e1029705.	2.1	7
106	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Reports, 2015, 13, 412-424.	2.9	387
107	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature, 2015, 526, 453-457.	13.7	191
108	Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. Immunotherapy, 2015, 7, 981-997.	1.0	5

#	Article	IF	Citations
109	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell, 2015, 162, 974-986.	13.5	1,408
110	Combination of Alphavirus Replicon Particleâ€“Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates. Cancer Immunology Research, 2014, 2, 448-458.	1.6	37
111	Modified Vaccinia Virus Ankara Triggers Type I IFN Production in Murine Conventional Dendritic Cells via a cGAS/STING-Mediated Cytosolic DNA-Sensing Pathway. PLoS Pathogens, 2014, 10, e1003989.	2.1	148
112	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. New England Journal of Medicine, 2014, 371, 2189-2199.	13.9	3,753
113	Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy. Science Translational Medicine, 2014, 6, 226ra32.	5.8	590
114	Immunotherapy and the belly of the beast. Journal of Experimental Medicine, 2014, 211, 2327-2328.	4.2	1
115	Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence. Cancer Research, 2014, 74, 2340-2350.	0.4	266
116	Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor. Cancer Immunology Research, 2014, 2, 70-79.	1.6	100
117	Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation. Cell, 2014, 156, 986-1001.	13.5	149
118	The importance of animal models in tumor immunity and immunotherapy. Current Opinion in Genetics and Development, 2014, 24, 46-51.	1.5	62
119	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. Cancer Discovery, 2014, 4, 538-545.	7.7	73
120	Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood, 2014, 123, 2172-2180.	0.6	23
121	T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks. ELife, 2014, 3, e01944.	2.8	57
122	GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability. Cancer Immunology Research, 2013, 1, 320-331.	1.6	135
123	Myeloid-derived suppressor cells and the efficacy of CD8+T-cell immunotherapy. OncoImmunology, 2013, 2, e22764.	2.1	6
124	Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent. PLoS ONE, 2013, 8, e82496.	1.1	11
125	Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. Journal of Experimental Medicine, 2012, 209, 2113-2126.	4.2	130
126	EWS-FLI-1-Targeted Cytotoxic T-cell Killing of Multiple Tumor Types Belonging to the Ewing Sarcoma Family of Tumors. Clinical Cancer Research, 2012, 18, 5341-5351.	3.2	39

#	Article	IF	Citations
127	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. New England Journal of Medicine, 2012, 367, 2316-2321.	13.9	222
128	Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. Cancer Cell, 2012, 22, 668-682.	7.7	469
129	Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment. Cancer Research, 2012, 72, 876-886.	0.4	313
130	Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF. Oncogene, 2012, 31, 446-457.	2.6	179
131	The immunological impact of the RAF inhibitor BMS908662: Preclinical and early clinical experience in combination with CTLA-4 blockade.. Journal of Clinical Oncology, 2012, 30, 2521-2521.	0.8	9
132	Innate Immune Response of Human Plasmacytoid Dendritic Cells to Poxvirus Infection Is Subverted by Vaccinia E3 via Its Z-DNA/RNA Binding Domain. PLoS ONE, 2012, 7, e36823.	1.1	32
133	Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. Vaccine, 2011, 29, 3646-3654.	1.7	12
134	Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope. PLoS ONE, 2011, 6, e21214.	1.1	12
135	Myxoma Virus Induces Type I Interferon Production in Murine Plasmacytoid Dendritic Cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-Dependent Pathway. Journal of Virology, 2011, 85, 10814-10825.	1.5	37
136	Monocytic CCR2+ Myeloid Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T Cell Infiltration Into the Tumor Microenvironment. Blood, 2011, 118, 2171-2171.	0.6	0
137	Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood, 2010, 115, 4384-4392.	0.6	98
138	Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation. PLoS ONE, 2010, 5, e10436.	1.1	222
139	Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity. PLoS ONE, 2010, 5, e12670.	1.1	57
140	Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. Journal of Experimental Medicine, 2010, 207, 637-650.	4.2	715
141	The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. Journal of Clinical Investigation, 2010, 120, 343-356.	3.9	62
142	OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. Journal of Experimental Medicine, 2009, 206, 1103-1116.	4.2	195
143	Self-antigenâ€“specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. Journal of Experimental Medicine, 2009, 206, 849-866.	4.2	92
144	Immune Rejection of Mouse Tumors Expressing Mutated Self. Cancer Research, 2009, 69, 3545-3553.	0.4	15

#	Article	IF	Citations
145	LRF Is an Essential Downstream Target of GATA1 in Erythroid Development and Regulates BIM-Dependent Apoptosis. Developmental Cell, 2009, 17, 527-540.	3.1	97
146	Development of effective vaccines for old mice in a tumor model. Vaccine, 2009, 27, 1093-1100.	1.7	6
147	Vaccinia Virus Subverts a Mitochondrial Antiviral Signaling Protein-Dependent Innate Immune Response in Keratinocytes through Its Double-Stranded RNA Binding Protein, E3. Journal of Virology, 2008, 82, 10735-10746.	1.5	49
148	Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine Melanoma. Cancer Research, 2008, 68, 9884-9891.	0.4	27
149	Mechanisms of Immunization Against Cancer Using Chimeric Antigens. Molecular Therapy, 2008, 16, 773-781.	3.7	17
150	The T Cell Cytolytic Molecules Fas Ligand and TRAIL, the Trafficking Molecules CCR9, Î²7 Integrin and PSGL-1, and the Immune Modulating Molecules OX40, CEACAM1, and CTLA4 Are Required for Thymic Graft-Versus-Host Disease. Blood, 2008, 112, 65-65.	0.6	12
151	Regulation of B Versus T Lymphoid Lineage Fate Decision by the Proto-Oncogene LRF. Science, 2007, 316, 860-866.	6.0	190
152	Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody.. Blood, 2007, 110, 1788-1788.	0.6	2
153	Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity. Cancer Research, 2006, 66, 4904-4912.	0.4	195
154	Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. Journal of Clinical Investigation, 2006, 116, 1382-1390.	3.9	80
155	LRF/Pokemon Plays a Pivotal Role in B Versus T Lymphoid Lineage Fate Decision at the Early Lymphoid Progenitor Stage by Opposing Notch1 Signaling.. Blood, 2006, 108, 778-778.	0.6	0
156	Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature, 2005, 433, 278-285.	13.7	461
157	Disruption of PLZP in Mice Leads to Increased T-Lymphocyte Proliferation, Cytokine Production, and Altered Hematopoietic Stem Cell Homeostasis. Molecular and Cellular Biology, 2004, 24, 10456-10469.	1.1	53
158	Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood, 2004, 103, 2358-2362.	0.6	64
159	POKEMON Is a Proto-Oncogene Which Plays a Key Role in Lymphomagenesis.. Blood, 2004, 104, 3489-3489.	0.6	1
160	Plzf Mediates Transcriptional Repression of HoxD Gene Expression through Chromatin Remodeling. Developmental Cell, 2002, 3, 499-510.	3.1	160
161	Atypical t(15;17)(q13;q12) in a patient with all-trans retinoic acid refractory secondary acute promyelocytic leukemia:. Cancer Genetics and Cytogenetics, 2002, 138, 143-148.	1.0	5
162	Maternally transmitted severe glucose 6-phosphate dehydrogenase deficiency is an embryonic lethal. EMBO Journal, 2002, 21, 4229-4239.	3.5	123

#	Article	IF	Citations
163	Modeling Acute Promyelocytic Leukemia in the Mouse: New Insights in the Pathogenesis of Human Leukemias. Blood Cells, Molecules, and Diseases, 2001, 27, 231-248.	0.6	12
164	Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6853-6858.	3.3	71
165	BCL-6 regulates chemokine gene transcription in macrophages. Nature Immunology, 2000, 1, 214-220.	7.0	164
166	In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene, 1999, 18, 5278-5292.	2.6	99
167	Pre-Existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. SSRN Electronic Journal, 0, , .	0.4	0
168	Pulsatile MEK Inhibition Improves Anti-Tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. SSRN Electronic Journal, 0, , .	0.4	0
169	T Cell Immunotherapies Trigger Neutrophil Activation to Eliminate Tumor Antigen Escape Variants. SSRN Electronic Journal, 0, , .	0.4	1